{
     "PMID": "11927184",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20020507",
     "LR": "20150311",
     "IS": "0893-133X (Print) 0893-133X (Linking)",
     "VI": "26",
     "IP": "5",
     "DP": "2002 May",
     "TI": "Effects of haloperidol and risperidone on neurotensin levels in brain regions and neurotensin efflux in the ventral striatum of the rat.",
     "PG": "595-604",
     "AB": "Neurotensin (NT) may play a role in the pathophysiology of schizophrenia and in the mechanism of action of antipsychotic drugs. Here we studied the effects of a 30-day regimen of haloperidol (1.15 mg/100 g food) and risperidone (1.15 and 2.3 mg/100 g food) on NT-like immunoreactivity (-LI) levels in brain tissue and NT-LI efflux in the ventral striatum (VSTR) of the rat. Haloperidol, but not risperidone, increased NT-LI levels in the striatum. In the occipital cortex, risperidone, but not haloperidol, decreased levels of NT-LI. In the hippocampus and the frontal cortex both haloperidol and risperidone (the higher dose) increased NT-LI levels. In the VSTR, haloperidol and risperidone (the higher dose) decreased NT-LI efflux and abolished the stimulatory effect of d-amphetamine (1.5 mg/kg, s.c.). Thus, changes in NT occur in response to antipsychotic drugs and psychostimulants that may be relevant for the pathophysiology and treatment of schizophrenia.",
     "FAU": [
          "Gruber, Susanne H M",
          "Nomikos, George G",
          "Mathe, Aleksander A"
     ],
     "AU": [
          "Gruber SH",
          "Nomikos GG",
          "Mathe AA"
     ],
     "AD": "Institution of Clinical Neuroscience, Karolinska Institutet, St. Gorans Hospital, S-112 81 Stockholm, Sweden.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "PL": "England",
     "TA": "Neuropsychopharmacology",
     "JT": "Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology",
     "JID": "8904907",
     "RN": [
          "0 (Antipsychotic Agents)",
          "0 (Central Nervous System Stimulants)",
          "0 (Dialysis Solutions)",
          "39379-15-2 (Neurotensin)",
          "J6292F8L3D (Haloperidol)",
          "L6UH7ZF8HC (Risperidone)",
          "TZ47U051FI (Dextroamphetamine)"
     ],
     "SB": "IM",
     "MH": [
          "Animals",
          "Antipsychotic Agents/blood/metabolism/*pharmacology",
          "Basal Ganglia/drug effects/metabolism/secretion",
          "Brain/*drug effects/*metabolism/secretion",
          "Central Nervous System Stimulants/pharmacology",
          "Dextroamphetamine/pharmacology",
          "Dialysis Solutions/metabolism",
          "Haloperidol/blood/metabolism/*pharmacology",
          "Male",
          "Microdialysis",
          "Neurotensin/*metabolism/*secretion",
          "Rats",
          "Rats, Wistar",
          "Risperidone/blood/metabolism/*pharmacology",
          "Tissue Distribution/drug effects"
     ],
     "EDAT": "2002/04/03 10:00",
     "MHDA": "2002/05/08 10:01",
     "CRDT": [
          "2002/04/03 10:00"
     ],
     "PHST": [
          "2002/04/03 10:00 [pubmed]",
          "2002/05/08 10:01 [medline]",
          "2002/04/03 10:00 [entrez]"
     ],
     "AID": [
          "S0893133X01003979 [pii]",
          "10.1016/S0893-133X(01)00397-9 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Neuropsychopharmacology. 2002 May;26(5):595-604. doi: 10.1016/S0893-133X(01)00397-9.",
     "term": "hippocampus"
}